Plasma NfL was also associated with a decrease in glucose metabolism and increase in atrophy in AD-vulnerable regions in Aβ+ participants (FDG PET SUVR change: Aβ+ CU, r = −0.24, P = .08; Aβ+ CImp, r = −0.23, P = .002; gray matter volume change: Aβ+ CU, r = −0.23, P = .02; Aβ+ CImp, r = −0.13, P = .01) (eFigure 15 in Supplement 1). Here, NEFL is linked to Alzheimer disease.